Transplant Hepatologist @westernuGI| MASH, MetALD, PTMS | @MayoClinicGIHep @Columbia Alum|@humasaeedulhaq's Husband|Girl Dad👨👩👧👧 | Musician🎸🎤| 🇨🇦🇵🇰
London, Ontario
Joined December 2019
- Tweets1.3K
- Following722
- Followers1.4K
- Likes2.2K
Pinned Tweet
1/🌙Ramadan Kareem #LiverX #LiverTwitter friends! For all those caring for Ramadan fasting liver patients, 👀 our practical guidance in @LancetGastroHep : tinyurl.com/27vrbrx4. 🔑 points / 🧵:
🌎 >1.8 billion Muslims; ~9⃣0⃣% observe Ramadan
🚫 🥤🍲 from sunrise🌅 to sunset🌇
Excited to be a part of the inaugural @TheLiverSummit in Dallas-FTW! A true pleasure to join this esteemed panel of liver leaders!
📢Join us on September 26, 2026 #livertwitter.
Obesity medicine & metabolic health take center stage at #TLS2026
Practical, multidisciplinary care at the intersection of hepatology and cardiometabolic health
DFW, TX | Sept 26
6 CME credits | Complimentary registration | Livestream available
Register texaslivercare.org/event/the…
Qasim Khan, MBBS, MS, FRCPC retweeted
GLP-1 drugs in people with obesity (no diabetes) and the link to reduction of cancer
Among nearly 230,000 individuals, there was >40% overall reduction in 13 cancers associated with obesity with just 2 years of follow-up. Not proof of cause and effect, but consistent with many recent reports on the link between GLP-1 drugs with less cancer
annalsofoncology.org/article…
Qasim Khan, MBBS, MS, FRCPC retweeted
🟣Very low energy ketogenic diet vs. Mediterranean diet for #MASLD: Superior steatosis reduction in a randomised pilot study
🔓#OpenAccess at👉 jhep-reports.eu/article/S258…
#MASLD #LiverTwitter #LiverX #LiverHealth
Qasim Khan, MBBS, MS, FRCPC retweeted
¿Cuándo elegir semaglutida y cuándo tirzepatida?
La EASO acaba de actualizar su algoritmo con evidencia hasta noviembre 2025 📊 @EASOobesity
Spoiler: depende del objetivo clínico. No es solo pérdida de peso.
🔗 @NatureMedicine
nature.com/articles/s41591-0…
#ECO2026
🗣️Compelling results for management of 🍻AUD using everyone’s fav GLP-1RAs 🦎:
Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial - The Lancet thelancet.com/journals/lance…
Qasim Khan, MBBS, MS, FRCPC retweeted
The weight-loss-independent hepatoprotective benefits of semaglutide are orchestrated by intrahepatic sinusoidal endothelial GLP-1 receptors.
cell.com/cell-metabolism/abs…
Qasim Khan, MBBS, MS, FRCPC retweeted
New MASLD review by Rinella & Sookoian in @NatRevGastroHep outlines a personalized roadmap for #MASH care, integrating metabolic, liver-directed, and lifestyle therapies. With resmetirom & semaglutide available, there is opportunity for combo strategies, biomarkers & precision medicine.
nature.com/articles/s41575-0…
Qasim Khan, MBBS, MS, FRCPC retweeted
This systematic review and meta-regression of 48 studies finds that after stopping GLP-1 receptor agonists, people regain weight in a predictable curve: about 60% of lost weight is back by 1 year, with regain eventually plateauing around 75% at 60 weeks.
thelancet.com/journals/eclin…
Qasim Khan, MBBS, MS, FRCPC retweeted
A detailed look at the hepatic spatial proteome @NatMetabolism nature.com/articles/s42255-0…
Qasim Khan, MBBS, MS, FRCPC retweeted
Here is a brief study summary defining the ATANGO score for the diagnosis and prognosis of patients with ACLF. ✅Simple to use✅diagnoses 12% more ✅16% patients reclassified. journal-of-hepatology.eu/act…
@YaqritLtd
a-tango.eu
@JHepatology
@EASLnews
@uclnews
Qasim Khan, MBBS, MS, FRCPC retweeted
GLP‑1 medicines act on pancreas, brain, heart, liver, kidney, vessels and adipose tissue, lowering events from HFpEF to PAD, CKD, OSA and potentially substance use and neurodegeneration.
nature.com/articles/s41591-0…
4/ Cirrhosis ➡️ nutritional risks in fasting 💪. TIPS:
1⃣ High protein suhoor & iftar (1.2-1.5 g/kg/day)
2⃣ Minimize long fasting gaps
3⃣ Post-iftar / late-night snack 🍗🧃
🏥LTX Recipients (1-year post):
- 1X/day 💊 IS (1-3 mo prior)
- ⬆️🥤
- 👀TAC lvls, RFTs
Qasim Khan, MBBS, MS, FRCPC retweeted
🌏 South Asia has the highest #IschemicHeartDisease burden 🫀. Men have higher mortality overall, but in Pakistan, women face greater risk. Key drivers for women: high blood pressure & low veg/fiber intake 🥦📉.
Get the details in #JACCAsia: jacc.org/doi/10.1016/j.jacas… #ACCIntl
Qasim Khan, MBBS, MS, FRCPC retweeted
New obesity guideline release 💯
American Diabetes Association Pharmacologic Treatment of Obesity in Adults: Standards of Care in Overweight and Obesity
ADA adds to the list of guidelines published this past year summarizing the evidence of obesity medications.
A particular emphasis on selecting a treatment based on the particular concurrent obesity comorbidities present.
diabetesjournals.org/docm-ca…
Qasim Khan, MBBS, MS, FRCPC retweeted
The Liver Summit International | Ecuador 🇪🇨
This week, TLS delivered focused, high-yield clinical education across two leading centers in Guayaquil, including sessions on MASLD & the evolving landscape of anti-obesity therapies.
📍Interhospital
📍Hospital de Especialidades Alfredo Paulson
Nearly 100 clinicians engaged across both sites, excellent discussion & growing momentum for regional collaboration across Latin America.
Building toward TLS 2026.
#MASLD #GlobalHepatology
